Bone Short Long Term Debt vs Current Deferred Revenue Analysis

BBLG Stock

USD 0.95 0.05 5.56%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Short Long Term Debt and its Current Deferred Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Short Long Term Debt account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bone Biologics' Short Long Term Debt and Current Deferred Revenue is 0.74. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Short Long Term Debt and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Bone Biologics Corp are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Short Long Term Debt i.e., Bone Biologics' Short Long Term Debt and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.74

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

The current Selling General Administrative is estimated to decrease to about 2 M. The current Tax Provision is estimated to decrease to 2,133

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Net Receivables	Non Current Liabilities Total	Inventory	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.41	-0.39	-0.49	-0.34	0.24	0.67	-0.62	-0.51	-0.56	-0.74	-0.39	-0.3	-0.02	-0.2	-0.42	-0.52	-0.08	0.65	-0.15	0.67	-0.52	-0.23
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.26	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.72	-0.93	0.34	-0.23	0.18	0.81	-0.02	-0.23	-0.14	0.01	-0.8
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.24	0.73	-0.29	0.46	0.39	-0.57	-0.47	0.44	-0.38	0.43	0.94
Cash And Short Term Investments	-0.41	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.15	0.4	0.19	0.58	0.54	-0.16	-0.61	0.58	-0.48	0.55	0.64
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.26	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	0.03	0.18	0.02	0.43	0.47	-0.02	-0.66	0.07	-0.59	0.34	0.56
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.25	0.68	0.46	0.38	0.28	0.71	-0.48	0.52	-0.06	0.41	0.31	-0.29	0.16	-0.34	0.3	-0.31
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.73	0.93	-0.36	0.19	-0.23	-0.82	0.09	0.23	0.2	-0.05	0.77
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.32	-0.24	-0.3	-0.76	-0.83	0.05	0.96	-0.5	0.97	-0.91	-0.46
Other Stockholder Equity	-0.62	0.59	-0.12	0.62	0.66	0.59	0.6	0.25	0.06	-0.96		0.23	0.26	0.93	0.74	0.24	0.33	0.22	0.73	0.84	-0.14	-0.93	0.6	-0.92	0.91	0.61
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.76	-0.76	0.32	0.02	0.45	0.72	-0.36	-0.09	-0.45	0.27	-0.49
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.48	-0.63	0.18	0.0	0.44	0.6	-0.35	-0.27	-0.48	0.21	-0.3
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.41	0.18	0.29	0.71	0.78	0.03	-0.9	0.55	-0.88	0.84	0.44
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		0.04	0.55	0.33	0.77	0.54	-0.25	-0.72	0.61	-0.59	0.65	0.66
Short Term Debt	-0.3	-0.26	0.72	-0.24	0.15	-0.26	0.03	0.71	-0.73	-0.32	0.24	0.76	0.48	0.41	0.04		-0.64	0.16	0.04	0.54	0.57	-0.33	0.37	-0.34	0.4	-0.37
Net Tangible Assets	-0.02	0.72	-0.93	0.73	0.4	0.72	0.18	-0.48	0.93	-0.24	0.33	-0.76	-0.63	0.18	0.55	-0.64		-0.18	0.44	-0.06	-0.83	-0.21	0.31	-0.09	0.19	0.83
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.16	-0.18		0.31	0.09	0.33	-0.28	0.07	-0.29	0.22	-0.33
Long Term Debt	-0.42	0.44	-0.23	0.46	0.58	0.44	0.43	-0.06	0.19	-0.76	0.73	0.02	0.0	0.71	0.77	0.04	0.44	0.31		0.51	0.07	-0.8	0.53	-0.67	0.67	0.47
Net Receivables	-0.52	0.32	0.18	0.39	0.54	0.32	0.47	0.41	-0.23	-0.83	0.84	0.45	0.44	0.78	0.54	0.54	-0.06	0.09	0.51		0.15	-0.77	0.57	-0.84	0.9	0.36
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.57	-0.83	0.33	0.07	0.15		-0.06	-0.12	-0.06	-0.03	-0.69
Inventory	0.65	-0.45	-0.02	-0.47	-0.61	-0.45	-0.66	-0.29	0.09	0.96	-0.93	-0.36	-0.35	-0.9	-0.72	-0.33	-0.21	-0.28	-0.8	-0.77	-0.06		-0.47	0.95	-0.84	-0.46
Short Long Term Debt	-0.15	0.39	-0.23	0.44	0.58	0.39	0.07	0.16	0.23	-0.5	0.6	-0.09	-0.27	0.55	0.61	0.37	0.31	0.07	0.53	0.57	-0.12	-0.47		-0.33	0.74	0.44
Property Plant Equipment	0.67	-0.35	-0.14	-0.38	-0.48	-0.35	-0.59	-0.34	0.2	0.97	-0.92	-0.45	-0.48	-0.88	-0.59	-0.34	-0.09	-0.29	-0.67	-0.84	-0.06	0.95	-0.33		-0.84	-0.37
Current Deferred Revenue	-0.52	0.38	0.01	0.43	0.55	0.38	0.34	0.3	-0.05	-0.91	0.91	0.27	0.21	0.84	0.65	0.4	0.19	0.22	0.67	0.9	-0.03	-0.84	0.74	-0.84		0.44
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.37	0.83	-0.33	0.47	0.36	-0.69	-0.46	0.44	-0.37	0.44

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	51.1K	43.1K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	1.0M	30.8K	6.7M	8.5M	3.7M	2.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Other Stockholder Equity	55.1M	55.2M	77.0M	77.9M	83.8M	47.8M
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Net Tangible Assets	(8.6M)	(11.9M)	(13.7M)	6.6M	7.6M	7.9M
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	11.3M	12.2M	99.9K	888.46	799.61	759.63
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:

How To Invest In Bone

Details

Is Bone Stock a good investment?

Details

What is Bone Biologics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.46)

Return On Assets

(0.57)

Return On Equity

(1.19)

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Short Long Term Debt vs Current Deferred Revenue Analysis

Short Long Term Debt vs Current Deferred Revenue

Short Long Term Debt vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Current Deferred Revenue

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.97	Retained Earnings
Inventory	+ 0.96	Retained Earnings
Property Plant Equipment	+ 0.95	Inventory

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Inventory	- 0.93	Other Stockholder Equity
Short Long Term Debt Total	- 0.93	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Property Plant Equipment	- 0.92	Other Stockholder Equity